Human mesenchymal stem cells & media

Human mesenchymal stem cells & media
Product Description

Lonza Biologics Inc offers wide range of pharma products and services which includes human mesenchymal stem cells & media. It belongs to primary and adult stem cells adult stem cells & media services & products category. It includes hmsc human mesenchymal stem cells, hmsc mesenchymal stem cell adipogenic differentiation medium, hmsc mesenchymal stem cell chondrocyte differentiation medium, hmsc mesenchymal stem cell osteogenic differentiation medium, mscgm™ mesenchymal stem cell growth medium, therapeak™ mscgm-cd™ mesenchymal stem cell medium, chemically defined.

Lonza Capsules & Health Ingredients

  • CH
  • 2015
    On CPHI since

Lonza Capsules & Health Ingredients

  • CH
  • 2015
    On CPHI since

More Products from Lonza Capsules & Health Ingredients (52)

  • Biological assays

    Product Biological assays

    Lonza Biologics Inc offers wide range of pharma products and services which includes biological assays. It belongs to pharma & biotech, bioassay services category. It includes cell proliferation, cell permeability, apoptosis, cell differentiation, cell survival/cytotoxicity, immunoassays: elisa, flow cytom...
  • Biopreservation, fill and finish

    Product Biopreservation, fill and finish

    Lonza Biologics Inc offers wide range of pharma products and services which includes biopreservation, fill and finish. It belongs to cell therapy products and services category. It recognize the unique time constraints associated with converting a cultured cell harvest into a formulated cell therapy product.
  • Cho cell media

    Product Cho cell media

    Lonza Biologics Inc offers wide range of pharma products and services which includes cho cell media. It belongs to upstream serum-free media and feed formulations services and products category. Contact us for more information.
  • Nucleofector™ devices

    Product Nucleofector™ devices

    Lonza Biologics Inc offers wide range of pharma products and services which includes nucleofector™ devices. It belongs to bioresearch transfection services and produtcs category. It includes 4d-nucleofector™ system, 96-well shuttle™ system, ht nucleofector™ system, nucleofector™ 2b...
  • Custom powdered media

    Product Custom powdered media

    Lonza Biologics Inc offers wide range of pharma products and services which includes custom powdered media . It belongs to upstream serum-free media and feed formulations services and products category. Features: non animal origin facility, relative humidity, consistent particl size distribution, batch cap...
  • Nucleofector™ kit accessories

    Product Nucleofector™ kit accessories

    Lonza Biologics Inc offers wide range of pharma products and services which includes nucleofector™ kit accessories. It belongs to bioresearch transfection services and produtcs category. . It includes nucleofector™ plus supplement, mouse t cell nucleofector™ medium, pmaxcloning™. It is ...
  • Nucleofector™ technology

    Product Nucleofector™ technology

    Lonza Biologics Inc offers wide range of pharma products and services which includes nucleofector™ technology. It belongs to bioresearch transfection services and produtcs category. It is a technology based on the momentary creation of small pores in cell membranes by applying an electrical pulse (ele...
  • Pluripotent stem cell services

    Product Pluripotent stem cell services

    Lonza Biologics Inc offers wide range of pharma products and services which includes pluripotent stem cell services. It belongs to pluripotent stem cells services category. It includes pharmaceutical companies looking to implement more biologically relevant cell models into their screening campaigns, trans...
  • Primary cells media

    Product Primary cells media

    Lonza Biologics Inc offers wide range of pharma products and services which includes primary cells media. It belongs to upstream serum-free media and feed formulations services and products category. Contact us for more information.
  • Process development services

    Product Process development services

    Lonza Biologics Inc offers wide range of pharma products and services which includes process development services. It belongs to cell therapy products and services category. It includes tissue acquisition, process development, media development. Contact us for more information.
  • Integrated technologies

    Product Integrated technologies

    Lonza Biologics Inc offers wide range of pharma products and services which includes integrated technologiesLonza Biologics Inc offers wide range of pharma products and services which includes integrated technologies. It belongs to pharma & biotech, informatics moda™ , paperless qc micro solution ser...
  • Cell Therapy Manufacturing Capabilities

    Product Cell Therapy Manufacturing Capabilities

    With more than 40 years of experience in normal human cells and best-in-class cGMP compliance, Lonza Walkersville, Inc. is the industry leader in development, manufacturing and testing services for cell-based therapeutics. Our R&D organization has a wide range of expertise in technology and media deve...

Lonza Capsules & Health Ingredients resources (6)

  • News CPHI North America 2023 – From the Floor

    Follow along for live updates from the Content team as we bring you the latest from CPHI North America 2023 - from session talks, panel discussions, interviews, and more, there's a lot to discover with CPHI Online at the Pennsylvania Convention Center! 
  • Video Lonza

    Enabling a healthier world.
  • News Lonza signs five-year collaboration deal with VC firm Bioqube to speed up portfolio companies’ development and manufacturing

    The offering will accelerate timelines for the development and manufacturing of molecules and disruptive technologies
  • Video Making a Splash in the US Market: How PBPK Modeling is Playing a Central Role in Risk Reduction in Early Drug Development

    Rapid and efficient development of drug candidates is increasingly important for pharmaceutical companies with accelerated timelines and funding constraints. However, many early drug candidates have poor oral absorption properties making it challenging to achieve target pharmacokinetic (PK) profiles. Without upfront knowledge of absorption risks and mitigation strategies, poor absorption can significantly impact preclinical and clinical study timelines and costs. Physiologically-based pharmacokinetic (PBPK) modeling software, such as the GastroPlus® platform from Simulations Plus, simulates dynamic physiological factors impacting oral performance. When coupled with in vitro measurements, PBPK modeling is effective in early development for 1) identifying absorption risks, 2) assessing the potential for solubility enhancing formulations such as salts, cocrystals, or amorphous solid dispersions to mitigate these risks, and 3) designing and optimizing preclinical and clinical studies with respect to dose, prandial state, or gastric pH modification to maximize the likelihood of achieving desired PK profiles. In this presentation, we will demonstrate how PBPK models combined with Lonza’s custom and off-the shelf in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development, reducing the need for drug product reformulation or repeated preclinical or clinical studies. Key Learning Objectives: Learn how PBPK modeling can identify potential oral absorption risks and mitigation strategies (e.g. bioavailability enhancement) for early drug candidates. Learn how PBPK modeling coupled with in vitro testing can guide early selection of drug form and formulation to achieve clinical study goals. Gain insights into how key drug and formulation factors including solubility, permeability, and dissolution rate can impact absorption risks such as poor oral bioavailability, food-drug interactions, and pH-dependent DDI effects.
  • News Lonza Switzerland site to undergo expansion of microbial development capabilities

    The expansion includes the installation of a pilot suite with a 50-L fermenter and automation upgrades to accelerate clinical and commercial projects
  • News Lonza boosts exosome capability with Codiak BioSciences facility acquisition

    The companies will establish a Centre of Excellence focused on exosome manufacturing and characterization technologies